The DOI matches its Crossref record; 115 of the 115 references it cites were found in a registry or an index.
Pharmacology of Systemic Antifungal Agents
Abstract
Traditionally, many invasive fungal infections were associated with a poor prognosis, because effective therapeutic options were limited. The recent development of new antifungal agents has significantly contributed to the successful treatment of fungal diseases. These drugs offer novel mechanisms of action and expanded spectrums of activity over traditional treatment options. However, with these new agents comes the need for increased awareness of the potential interactions and toxicities associated with these drugs. Therefore, an understanding of the pharmacokinetic and pharmacodynamic properties of the classes of antifungal compounds is vital for the effective management of invasive fungal infections. This review provides a summary of the pharmacologic principles involved in treatment of fungal diseases.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Voriconazole versus Amphotericin B for Primary Therapy of Invasive Aspergillosis
Herbrecht, R., Denning, D. W., Patterson, T. F., Bennett, J. E., Greene, R. E., Oestmann, J.-W., Kern, W. V., Marr, K. A., Ribaud, P., Lortholary, O., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa020191 · Cited by 3,304
Updated definitions of healthy ranges for serum alanine aminotransferase levels
Prati, D., Taioli, E., Zanella, A., Torre, E. D., Butelli, S., Del Vecchio, E., Vianello, L., Zanuso, F., Mozzi, F., Milani, S., et al. (2002) · Annals of Internal Medicine · doi:10.7326/0003-4819-137-1-200207020-00006 · Cited by 1,445
Guidelines for Treatment of Candidiasis
Pappas, P. G., Rex, J. H., Sobel, J. D., Filler, S. G., Dismukes, W. E., Walsh, T. J., & Edwards, J. E. (2004) · Clinical Infectious Diseases · doi:10.1086/380796 · Cited by 1,440
Current and emerging azole antifungal agents
Sheehan, D. J., Hitchcock, C. A., & Sibley, C. M. (1999) · Clinical Microbiology Reviews · doi:10.1128/cmr.12.1.40 · Cited by 1,137
Practice Guidelines for the Management of Cryptococcal Disease
Saag, M. S., Graybill, R. J., Larsen, R. A., Pappas, P. G., Perfect, J. R., Powderly, W. G., Sobel, J. D., Dismukes, W. E., & Mycoses Study Group Cryptococcal Subproject (2000) · Clinical Infectious Diseases · doi:10.1086/313757 · Cited by 1,105
Amphotericin B: 30 Years of Clinical Experience
Gallis, H. A., Drew, R. H., & Pickard, W. W. (1990) · Clinical Infectious Diseases · doi:10.1093/clinids/12.2.308 · Cited by 1,009
Rex, J. H., Pfaller, M. A., Galgiani, J. N., Bartlett, M. S., Espinel-Ingroff, A., Ghannoum, M. A., Lancaster, M., Odds, F. C., Rinaldi, M. G., Walsh, T. J., et al. (1997) · Clinical Infectious Diseases · doi:10.1093/clinids/24.2.235 · Cited by 855
Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis
Denning, D. W., Ribaud, P., Milpied, N., Caillot, D., Herbrecht, R., Thiel, E., Haas, A., Ruhnke, M., & Lode, H. (2002) · Clinical Infectious Diseases · doi:10.1086/324620 · Cited by 844
Vermes, A. (2000) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/46.2.171 · Cited by 803
van Burik, J.-A. H., Ratanatharathorn, V., Stepan, D. E., Miller, C. B., Lipton, J. H., Vesole, D. H., Bunin, N., Wall, D. A., Hiemenz, J. W., Satoi, Y., et al. (2004) · Clinical Infectious Diseases · doi:10.1086/422312 · Cited by 744
Update: Clinically Significant Cytochrome P‐450 Drug Interactions
Michalets, E. L. (1998) · Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/j.1875-9114.1998.tb03830.x · Cited by 597
Espinel-Ingroff, A. (1998) · Journal of Clinical Microbiology · doi:10.1128/jcm.36.10.2950-2956.1998 · Cited by 576
Wingard, J. R., White, M. H., Anaissie, E., Raffalli, J., Goodman, J., Arrieta, A., & L Amph/ABLC Collaborative Study Group (2000) · Clinical Infectious Diseases · doi:10.1086/317451 · Cited by 527
Antifungal Susceptibility Survey of 2,000 Bloodstream Candida Isolates in the United States
Ostrosky-Zeichner, L., Rex, J. H., Pappas, P. G., Hamill, R. J., Larsen, R. A., Horowitz, H. W., Powderly, W. G., Hyslop, N., Kauffman, C. A., Cleary, J., et al. (2003) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.47.10.3149-3154.2003 · Cited by 498
Pharmacokinetics and Safety of Voriconazole following Intravenous- to Oral-Dose Escalation Regimens
Purkins, L., Wood, N., Ghahramani, P., Greenhalgh, K., Allen, M. J., & Kleinermans, D. (2002) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.46.8.2546-2553.2002 · Cited by 415
Amphotericin B: time for a new “gold standard”
Saravolatz, L. D., Ostrosky-Zeichner, L., Marr, K. A., Rex, J. H., & Cohen, S. H. (2003) · Clinical Infectious Diseases · doi:10.1086/376634 · Cited by 406
Pfaller, M. A., Messer, S. A., Hollis, R. J., & Jones, R. N. (2002) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.46.4.1032-1037.2002 · Cited by 404
Deray, G. (2002) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/49.suppl_1.37 · Cited by 400
Groll, A. H., Piscitelli, S. C., & Walsh, T. J. (1998) · Advances in pharmacology · doi:10.1016/s1054-3589(08)60129-5 · Cited by 377
Johnson, P. C., Wheat, L. J., Cloud, G. A., Goldman, M., Lancaster, D., Bamberger, D. M., Powderly, W. G., Hafner, R., Kauffman, C. A., Dismukes, W. E., et al. (2002) · Annals of Internal Medicine · doi:10.7326/0003-4819-137-2-200207160-00008 · Cited by 367
Courtney, R., Wexler, D., Radwanski, E., Lim, J., & Laughlin, M. (2004) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.2003.01977.x · Cited by 327
Bekersky, I., Fielding, R. M., Dressler, D. E., Lee, J. W., Buell, D. N., & Walsh, T. J. (2002) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.46.3.828-833.2002 · Cited by 319
Hariprasad, S. M. (2004) · Archives of Ophthalmology · doi:10.1001/archopht.122.1.42 · Cited by 312
Tawara, S., Ikeda, F., Maki, K., Morishita, Y., Otomo, K., Teratani, N., Goto, T., Tomishima, M., Ohki, H., Yamada, A., et al. (2000) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.44.1.57-62.2000 · Cited by 311
Newer Systemic Antifungal Agents: Pharmacokinetics, Safety and Efficacy
Boucher, H. W., Groll, A. H., Chiou, C. C., & Walsh, T. J. (2004) · Drugs · doi:10.2165/00003495-200464180-00001 · Cited by 305
White, M. H., Bowden, R. A., Sandler, E. S., Graham, M. L., Noskin, G. A., Wingard, J. R., Goldman, M., van Burik, J., McCabe, A., Lin, J., et al. (1998) · Clinical Infectious Diseases · doi:10.1086/514672 · Cited by 303
Rex, J. H., Pfaller, M. A., Barry, A. L., Nelson, P. W., & Webb, C. D. (1995) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.39.1.40 · Cited by 301
Pfaller, M. A., Jones, R. N., Doern, G. V., Sader, H. S., Hollis, R. J., Messer, S. A., & Group, F. T. S. P. (1998) · Journal of Clinical Microbiology · doi:10.1128/jcm.36.7.1886-1889.1998 · Cited by 281
Niwa, T., Shiraga, T., & Takagi, A. (2005) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.28.1805 · Cited by 274
Amphotericin B Pharmacokinetics in Humans
Atkinson, A. J., & Bennett, J. E. (1978) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.13.2.271 · Cited by 267
Pfaller, M. A., Jones, R. N., Doern, G. V., Fluit, A. C., Verhoef, J., Sader, H. S., Messer, S. A., Houston, A., Coffman, S., & Hollis, R. J. (1999) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/s0732-8893(99)00046-2 · Cited by 264
Lutsar, I., Roffey, S., & Troke, P. (2003) · Clinical Infectious Diseases · doi:10.1086/377131 · Cited by 262
Mode of action of 5-fluorocytosine and mechanisms of resistance
Polak, A., & Scholer, H. J. (2009) · Chemotherapy · doi:10.1159/000221854 · Cited by 250 · cited 1×
“Unfortunately, the toxicity of this agent and the rapid development of resistance when used as monotherapy have precluded its routine use for the treatment of other invasive infections [5, 32, 33].”
Bekersky, I., Fielding, R. M., Dressler, D. E., Lee, J. W., Buell, D. N., & Walsh, T. J. (2002) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.46.3.834-840.2002 · Cited by 236
Interaction of Common Azole Antifungals with P Glycoprotein
Wang, E.-J., Lew, K., Casciano, C. N., Clement, R. P., & Johnson, W. W. (2002) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.46.1.160-165.2002 · Cited by 233
Francis, P., & Walsh, T. J. (1992) · Clinical Infectious Diseases · doi:10.1093/clind/15.6.1003 · Cited by 232
Disposition of Posaconazole following Single-Dose Oral Administration in Healthy Subjects
Krieter, P., Flannery, B., Musick, T., Gohdes, M., Martinho, M., & Courtney, R. (2004) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.48.9.3543-3551.2004 · Cited by 212
Barone, J. A., Moskovitz, B. L., Guarnieri, J., Hassell, A. E., Colaizzi, J. L., Bierman, R. H., & Jessen, L. (1998) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.42.7.1862 · Cited by 208
Penetration of new azole compounds into the eye and efficacy in experimental Candida endophthalmitis
Savani, D. V., Perfect, J. R., Cobo, L. M., & Durack, D. T. (1987) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.31.1.6 · Cited by 202
Congestive heart failure associated with itraconazole
Ahmad, S. R., Singer, S. J., & Leissa, B. G. (2001) · The Lancet · doi:10.1016/s0140-6736(00)04891-1 · Cited by 200
Effect of posaconazole on cytochrome P450 enzymes: a randomized, open-label, two-way crossover study
Wexler, D., Courtney, R., Richards, W., Banfield, C., Lim, J., & Laughlin, M. (2004) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2004.01.005 · Cited by 199
Detection of amphotericin B-resistant Candida isolates in a broth-based system
Rex, J. H., Cooper, C. R., Merz, W. G., Galgiani, J. N., & Anaissie, E. J. (1995) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.39.4.906 · Cited by 198
Organism-Dependent Fungicidal Activities of Azoles
Manavathu, E. K., Cutright, J. L., & Chandrasekar, P. H. (1998) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.42.11.3018 · Cited by 190
Pharmacodynamics of amphotericin B in a neutropenic-mouse disseminated-candidiasis model
Andes, D., Stamsted, T., & Conklin, R. (2001) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.45.3.922-926.2001 · Cited by 180
Self-citationHebert, M. F., Smith, H. E., Marbury, T. C., Swan, S. K., Smith, W. B., Townsend, R. W., Buell, D., Keirns, J., & Bekersky, I. (2005) · The Journal of Clinical Pharmacology · doi:10.1177/0091270005279580 · Cited by 180
Krause, D. S., Reinhardt, J., Vazquez, J. A., Reboli, A., Goldstein, B. P., Wible, M., & Henkel, T. (2004) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.48.6.2021-2024.2004 · Cited by 179
Pharmacodynamics of a new triazole, posaconazole, in a murine model of disseminated candidiasis
Andes, D., Marchillo, K., Conklin, R., Krishna, G., Ezzet, F., Cacciapuoti, A., & Loebenberg, D. (2004) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.48.1.137-142.2004 · Cited by 177
Self-citationThe effects of food and dose on the oral systemic availability of itraconazole in healthy subjects
Van Peer, A., Woestenborghs, R., Heykants, J., Gasparini, R., & Gauwenbergh, G. (1989) · European Journal of Clinical Pharmacology · doi:10.1007/bf00558308 · Cited by 176
Zimmermann, T., Yeates, R. A., Laufen, H., Pfaff, G., & Wildfeuer, A. (1994) · European Journal of Clinical Pharmacology · doi:10.1007/bf00199879 · Cited by 173
Population Pharmacokinetic Analysis of Anidulafungin, an Echinocandin Antifungal
Dowell, J. A., Knebel, W., Ludden, T., Stogniew, M., Krause, D., & Henkel, T. (2004) · The Journal of Clinical Pharmacology · doi:10.1177/0091270004265644 · Cited by 170
Arndt, C. A. S., Walsh, T. J., McCully, C. L., Balis, F. M., Pizzo, P. A., & Poplack, D. G. (1988) · Journal of Infectious Diseases · doi:10.1093/infdis/157.1.178 · Cited by 169
In Vivo Pharmacodynamics of Antifungal Drugs in Treatment of Candidiasis
Andes, D. (2003) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.47.4.1179-1186.2003 · Cited by 169
Self-citationPreliminary animal pharmacokinetics of the parenteral antifungal agent MK-0991 (L-743,872)
Hajdu, R., Thompson, R., Sundelof, J. G., Pelak, B. A., Bouffard, F. A., Dropinski, J. F., & Kropp, H. (1997) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.41.11.2339 · Cited by 165
Tassel, D. (1968) · JAMA · doi:10.1001/jama.206.4.830 · Cited by 164
Effect of food on the pharmacokinetics of multiple‐dose oral voriconazole
Purkins, L., Wood, N., Kleinermans, D., Greenhalgh, K., & Nichols, D. (2003) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.2003.01994.x · Cited by 163
High-dose itraconazole in the treatment of severe mycoses
Sharkey, P. K., Rinaldi, M. G., Dunn, J. F., Hardin, T. C., Fetchick, R. J., & Graybill, J. R. (1991) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.35.4.707 · Cited by 155
Pfaller, M. A., Messer, S. A., Hollis, R. J., & Jones, R. N. (2001) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.45.10.2862-2864.2001 · Cited by 146
Mechanisms of action of 5-fluorocytosine
Waldorf, A. R., & Polak, A. (1983) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.23.1.79 · Cited by 141
Effect of a Cola Beverage on the Bioavailability of Itraconazole in the Presence of H2 Blockers
Lange, D., Pavao, J. H., Wu, J., & Klausner, M. A. (1997) · The Journal of Clinical Pharmacology · doi:10.1002/j.1552-4604.1997.tb04332.x · Cited by 136
Effect of omeprazole on the pharmacokinetics of itraconazole
Jaruratanasirikul, S., & Sriwiriyajan, S. (1998) · European Journal of Clinical Pharmacology · doi:10.1007/s002280050438 · Cited by 135
Groll, A. H., Mickiene, D., Petraitienė, R., Petraitis, V., Lyman, C. A., Bacher, J., Piscitelli, S. C., & Walsh, T. J. (2001) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.45.10.2845-2855.2001 · Cited by 135
Tiphine, M., Letscher‐Bru, V., & Herbrecht, R. (1999) · Transplant Infectious Disease · doi:10.1034/j.1399-3062.1999.010406.x · Cited by 133
Denning, D. W., & Griffiths, C. E. M. (2001) · Clinical and Experimental Dermatology · doi:10.1046/j.1365-2230.2001.00909.x · Cited by 132
Pfaller, M. A., Messer, S. A., Boyken, L., Huynh, H., Hollis, R. J., & Diekema, D. J. (2002) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.46.11.3518-3521.2002 · Cited by 132
Courtney, R., Sansone, A., Smith, W. J., Marbury, T. C., Statkevich, P., Martinho, M., Laughlin, M. A., & Swan, S. K. (2005) · The Journal of Clinical Pharmacology · doi:10.1177/0091270004271402 · Cited by 132
Groll, A. H., Mickiene, D., Petraitis, V., Petraitienė, R., Ibrahim, K. H., Piscitelli, S. C., Bekersky, I., & Walsh, T. J. (2001) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.45.12.3322-3327.2001 · Cited by 128
Fluconazole Penetration into Cerebrospinal Fluid in Humans
Foulds, G. H., Brennan, D. R., Wajszczuk, C. P., Catanzaro, A., Garg, D. C., Knopf, W. D., Rinaldi, M. G., & Weidler, D. J. (1988) · The Journal of Clinical Pharmacology · doi:10.1002/j.1552-4604.1988.tb03159.x · Cited by 127
Marr, K. A., Hachem, R. Y., Papanicolaou, G. A., Somani, J., Arduino, J. M., Lipka, C. J., Ngai, A., Kartsonis, N. A., Chodakewitz, J., & Sable, C. (2004) · Transplant Infectious Disease · doi:10.1111/j.1399-3062.2004.00065.x · Cited by 117
de Velde, V. J. V., Peer, A. P. V., Heykants, J., Woestenborghs, R. J. H., Rooy, P. V., Beule, K. D., & Cauwenbergh, G. F. M. J. (1996) · PubMed · Cited by 116
Ocular Uptake of Fluconazole Following Oral Administration
O’Day, D. M. (1990) · Archives of Ophthalmology · doi:10.1001/archopht.1990.01070090108050 · Cited by 114
Roden, M. M., Nelson, L. D., Knudsen, T. A., Jarosinski, P. F., Starling, J. M., Shiflett, S. E., Calis, K. A., DeChristoforo, R., Donowitz, G. R., Buell, D. N., et al. (2003) · Clinical Infectious Diseases · doi:10.1086/374553 · Cited by 110
Flucytosine kinetics in subjects with normal and impaired renal function
Cutler, R. E., Blair, A. D., & Kelly, M. R. (1978) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt1978243333 · Cited by 109
Metabolites of Caspofungin Acetate, a Potent Antifungal Agent, in Human Plasma and Urine
Balani, S. K., Xu, X., Arison, B. H., da Silva, M. V. M., Gries, A., Deluna, F. A., Cui, D., Kari, P. H., Ly, T., Hop, C. E. C. A., et al. (2000) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(24)15072-6 · Cited by 104
González, G. M., Fothergill, A. W., Sutton, D. A., Rinaldi, M. G., & Loebenberg, D. (2005) · Medical Mycology · doi:10.1080/13693780500088416 · Cited by 103
In vivo pharmacodynamics of HMR 3270, a glucan synthase inhibitor, in a murine candidiasis model
Andes, D., Marchillo, K., Lowther, J., Bryskier, A., Stamstad, T., & Conklin, R. (2003) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.47.4.1187-1192.2003 · Cited by 100
Self-citationGauthier, G. M., Nork, T. M., Prince, R., & Andes, D. (2005) · Clinical Infectious Diseases · doi:10.1086/431761 · Cited by 99
Self-citationPotential for Interactions between Caspofungin and Nelfinavir or Rifampin
Stone, J. A., Migoya, E. M., Hickey, L., Winchell, G. A., Deutsch, P., Ghosh, K., Freeman, A., Bi, S., Desai, R., Dilzer, S. C., et al. (2004) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.48.11.4306-4314.2004 · Cited by 99
de Velde, V. J. S. V., Peer, A. P. V., Heykants, J., Woestenborghs, R. J. H., Rooy, P. V., Beule, K. D., & Cauwenbergh, G. F. M. J. (1996) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/j.1875-9114.1996.tb02973.x · Cited by 99
Barone, J. A., Moskovitz, B. L., Guarnieri, J. A., Hassell, A. E., Colaizzi, J. L., Bierman, R. H., & Jessen, L. M. (1998) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/j.1875-9114.1998.tb03856.x · Cited by 89
Potoski, B. A., & Brown, J. E. (2002) · Clinical Infectious Diseases · doi:10.1086/343746 · Cited by 88
Successful Use of Voriconazole for Treatment of Coccidioides Meningitis
Proia, L. A., & Tenorio, A. R. (2004) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.48.6.2341.2004 · Cited by 86
Pharmacokinetics/pharmacodynamics of echinocandins
Theuretzbacher, U. (2004) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-004-1228-z · Cited by 84
Lee, S.-C., Fung, C., Huang, J., Tsai, C.-J., Chen, K.-S., Chen, H.-Y., Lee, N., See, L., & Wb, S. (2000) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.44.10.2715-2718.2000 · Cited by 81
Vandewoude, K., Vogelaers, D., Decruyenaere, J., Jaqmin, P., De Beule, K., Van Peer, A., Woestenborghs, R., Groen, K., & Colardyn, F. (1997) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.41.12.2714 · Cited by 79
Effects of Voriconazole on Cryptococcus neoformans
van Duin, D., Cleare, W., Zaragoza, Ó., Casadevall, A., & Nosanchuk, J. D. (2004) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.48.6.2014-2020.2004 · Cited by 79
González, G. M., Tijerina, R., Najvar, L. K., Bocanegra, R. A., Luther, M. F., Rinaldi, M. G., & Graybill, J. R. (2001) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.45.6.1854-1859.2001 · Cited by 78
Louie, A., Liu, W., Miller, D. A., Sucke, A. C., Liu, Q., Drusano, G. L., Mayers, M., & Miller, M. H. (1999) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.43.12.2831 · Cited by 76
Barchiesi, F., Schimizzi, A. M., Fothergill, A. W., Scalise, G., & Rinaldi, M. G. (1999) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/pl00015011 · Cited by 74
Systemic Antifungal Therapy: New Options, New Challenges
Wong‐Beringer, A., & Kriengkauykiat, J. (2003) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.23.14.1441.31938 · Cited by 72
The disposition and metabolism of [14C]fluconazole in humans.
Brammer, K. W., Coakley, A. J., Jezequel, S. G., & Tarbit, M. H. (1991) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(25)08893-2 · Cited by 69
Alopecia Associated with Fluconazole Therapy
Pappas, P. G., Kauffman, C. A., Perfect, J. R., Johnson, P. C., McKinsey, D. S., Bamberger, D. M., Hamill, R., Sharkey, P. K., Chapman, S. W., & Sobel, J. D. (1995) · Annals of Internal Medicine · doi:10.7326/0003-4819-123-5-199509010-00006 · Cited by 68
Lass‐Flörl, C., Nagl, M., Speth, C., Ulmer, H., Dierich, M. P., & Würzner, R. (2001) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.45.1.124-128.2001 · Cited by 68
Arıkan, S., Paetznick, V. L., & Rex, J. H. (2002) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.46.9.3084-3087.2002 · Cited by 68
Nakai, T., Uno, J., Otomo, K., Ikeda, F., Tawara, S., Goto, T., Nishimura, K., & Miyaji, M. (2002) · Chemotherapy · doi:10.1159/000057666 · Cited by 67
Antifungal activity of itraconazole compared with hydroxy-itraconazole in vitro
Odds, F. C., & BOSSCHE, H. V. (2000) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/45.3.371 · Cited by 67
Penetration of Amphotericin B into the Human Eye
Fisher, J. F., Taylor, A. T., Clark, J. E., Rao, R., & Espinel-Ingroff, A. V. (1983) · The Journal of Infectious Diseases · doi:10.1093/infdis/147.1.164 · Cited by 66
Goldblum, D., Rohrer, K., Frueh, B. E., Theurillat, R., Thormann, W., & Zimmerli, S. (2002) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.46.12.3719-3723.2002 · Cited by 63
Voriconazole‐Induced Retinoid‐Like Photosensitivity in Children
Rubenstein, M., Levy, M. L., & Metry, D. W. (2004) · Pediatric Dermatology · doi:10.1111/j.0736-8046.2004.21614.x · Cited by 59
Johnson, M. D., Drew, R. H., & Perfect, J. R. (1998) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/j.1875-9114.1998.tb03934.x · Cited by 53
Johnson, M. D., Hamilton, C. D., Drew, R. H., Sanders, L. L., Pennick, G. J., & Perfect, J. R. (2003) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkg089 · Cited by 53
Influence of Human Serum on Antifungal Pharmacodynamics with Candida albicans
Zhanel, G. G., Saunders, D. G., Hoban, D. J., & Karlowsky, J. A. (2001) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.45.7.2018-2022.2001 · Cited by 50
Nephrotoxicity Associated with Combined Gentamicin – Amphotericin B Therapy
Churchill, D., & Seely, J. F. (2008) · The Nephron journals/Nephron journals · doi:10.1159/000180883 · Cited by 46
Barchiesi, F., Schimizzi, A. M., Fothergill, A. W., Scalise, G., & Rinaldi, M. G. (1999) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s100960050283 · Cited by 43
Murdoch, D., & Plosker, G. L. (2004) · Drugs · doi:10.2165/00003495-200464190-00011 · Cited by 40
Projecting future drug expenditures—2005
Hoffman, J. M., Shah, N. D., Vermeulen, L. C., Hunkler, R. J., & Hontz, K. M. (2005) · American Journal of Health-System Pharmacy · doi:10.1093/ajhp/62.2.149 · Cited by 39
Antony, S. J. (2004) · Clinical Infectious Diseases · doi:10.1086/423811 · Cited by 37
Influence of serum protein binding on theIn Vitro activity of anti-fungal agents
Schäfer‐Korting, M., Körting, H. C., Rittler, W., & Obermüller, W. (1995) · Infection · doi:10.1007/bf01716289 · Cited by 36
Mian, U. K., Mayers, M., GARG, Y., Liu, Q., NEWCOMER, G., Madu, C. N., Liu, W., Louie, A., & Miller, M. H. (1998) · Journal of Ocular Pharmacology and Therapeutics · doi:10.1089/jop.1998.14.459 · Cited by 35
The influence of gastric pH on the pharmacokinetics of fluconazole: the effect of omeprazole.
Zimmermann, T., Yeates, R. A., Riedel, K. D., Lach, P., & Laufen, H. (1994) · PubMed · Cited by 34
Martínez-Suárez, J. V., & Rodríguez-Tudela, J. L. (1995) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.39.7.1512 · Cited by 34
Schäfer‐Korting, M., Körting, H. C., Amann, F., Peuser, R., & Lukacs, A. (1991) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.35.10.2053 · Cited by 32
Ocular penetration of 5-fluorocytosine.
Walsh, A., Haft, D. A., Miller, M. H., Loran, M. R., & Friedman, A. H. (1978) · PubMed · Cited by 29
Recognition of extracellular matrix proteins byParacoccidioides brasiliensisyeast cells
González, Á., Gómez, B. L., Restrepo, Á., Hamilton, A. J., & Cano, L. E. (2005) · Medical Mycology · doi:10.1080/13693780500064599 · Cited by 23
Pfaller, M. A., Bale, M. J., Buschelman, B. J., & Rhomberg, P. R. (1994) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/0732-8893(94)90116-3 · Cited by 22
Anttila, V.-J., Piilonen, A. K., & Valtonen, M. (2003) · Scandinavian Journal of Infectious Diseases · doi:10.1080/00365540310016871 · Cited by 15
Cited by
Pappas, P. G., Kauffman, C. A., Andes, D. R., Clancy, C. J., Marr, K. A., Ostrosky-Zeichner, L., Reboli, A. C., Schuster, M. G., Vazquez, J. A., Walsh, T. J., et al. (2016) · Clinical Infectious Diseases · doi:10.1093/cid/civ933 · Cited by 4,200
Self-citationEpidemiology of Invasive Candidiasis: a Persistent Public Health Problem
Pfaller, M. A., & Diekema, D. J. (2007) · Clinical Microbiology Reviews · doi:10.1128/cmr.00029-06 · Cited by 4,174
Walsh, T. J., Anaissie, E. J., Denning, D. W., Herbrecht, R., Kontoyiannis, D. P., Marr, K. A., Morrison, V. A., Segal, B. H., Steinbach, W. J., Stevens, D. A., et al. (2008) · Clinical Infectious Diseases · doi:10.1086/525258 · Cited by 2,706
Pascual, A., Calandra, T., Bolay, S., Buclin, T., Bille, J., & Marchetti, O. (2008) · Clinical Infectious Diseases · doi:10.1086/524669 · Cited by 887
Antifungal therapeutic drug monitoring: established and emerging indications
Andes, D., Pascual, A., & Marchetti, O. (2009) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00705-08 · Cited by 490
Self-citation
Metadata
- Authors
- Ashley, E. S. D., Lewis, R., Lewis, J. S., Martin, C., & Andes, D.
- Venue
- Clinical Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2006-08-01
- Volume
- 43
- Issue
- Supplement_1
- Pages
- S28-S39
- ISSN
- 1058-4838 (ISSN-L)
- 1537-6591
- OpenAlex
- W1982177139
- Cited by
- 313
- References
- 115
- FWCI
- 9.94
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.